Search

Displaying results 1761 - 1770 of 4692 in total
  1. Drug

    Hyaluronidase (ovine)

    go.drugbank.com/drugs/DB00070
    Approved

    Highly purified sheep hyaluronidase for administration by injection into the vitreous of the eye.

  2. Drug

    Angiotensin II

    go.drugbank.com/drugs/DB11842
    ApprovedInvestigational

    As distributive shock is the most common type of shock in the inpatient setting and affects up to one third of patients in the intensive care unit, the FDA determined that there is a need for treatment

  3. Drug

    Oritavancin

    go.drugbank.com/drugs/DB04911
    ApprovedInvestigational

    It was developed by The Medicines Company (acquired by Novartis). … Marketed by Melinta Therapeutics, Kimyrsa offers effective and time-efficient treatment for skin and skin structure infections.[L32629]

  4. Drug

    Cefroxadine

    go.drugbank.com/drugs/DB11367
    ApprovedWithdrawn

    It was used in Italy but has since been withdrawn.

  5. Drug

    Sodium sulfide

    go.drugbank.com/drugs/DB11159
    Approved

    Along with its hydrate form, sodium sulfide releases hydrogen sulfide (H2S) when in contact with moist air.

  6. Drug

    Nifedipine

    go.drugbank.com/drugs/DB01115
    ApprovedInvestigational

    Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine]. … [A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.

    Products: NIFEDIPINO MK 10 MG. CAPSULAS
  7. Drug

    Mepolizumab

    go.drugbank.com/drugs/DB06612
    ApprovedInvestigational

    The pathogenesis of eosinophilia is complex, but IL-5 is recognized as a key cytokine involved in the differentiation, recruitment, activation, and prolonged survival of eosinophils in peripheral tissue … Mepolizumab was first approved by the FDA on November 4, 2015, as an add-on therapy for severe asthma and marketed under the brand name Nucala by GlaxoSmithKline.

  8. Drug

    OSI-7836

    go.drugbank.com/drugs/DB05837
    Experimental

    OSI-7836 is a member of the nucleoside class of cytotoxic drugs of which gemcitabine is the market leader. OSI Pharmaceuticals develops OSI-7836 as a next-generation gemcitabine. The anti-tumor activity of OSI-7836 appeares to be less sc...

  9. Drug

    Plozasiran

    go.drugbank.com/drugs/DB18997
    ApprovedInvestigational

    Plozasiran (ARO-APOC3) is a small interfering RNA (siRNA) that degrades apolipoprotein C-III (apoC-III) mRNA by RNA interference. … [L45864] Plozasiran was first approved by the FDA on November 18th, 2025, to reduce triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS).[L54603]

  10. Drug

    Bosentan

    go.drugbank.com/drugs/DB00559
    ApprovedInvestigational

    Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. … Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure.